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ABSTRACT
eart failure during pregnancy was described 
in 1849 but was first described as a distinctive 
1Hform of cardiomyopathy in the 1930s . In 
21971, Demakis et al  described 27 patients who 
presented during pueperium with cardiomegaly, 
abnormal electrocardiographic findings, congestive 
heart failure and named the syndrome “peripartum 
cardiomyopathy”.
3 The European Society of Cardiology defined 
Peripartum Cardiomyopathy (PC) as a form of dilated 
cardiomyopathy that presents with signs of heart 
failure in the last month of pregnancy or within 5 
months of delivery.
EPIDEMIOLOGY
Peripartum cardiomyopathy is a relatively rare 
4condition. In Nigeria, a rate of 1% has been reported . In 
South Africa, reported incidence is higher than 1 in 
41000  live births while 1 in 300 live births has been 
5reported in Haiti . In the United States, the reported 
incidence range from 1 in 1149 to 1 in 4350 live births 
6 , 7with  a  mean of  1  in  3186  l ive  b i r ths .
The higher prevalence in developing countries may be 
attributed to environmental, ecological, cultural, 
puerperal and post puerperal practices besides 
diagnostic criteria and reporting standards.
RISK FACTORS
The incidence of PCis higher in multiparity, advance 
maternal age, multiple pregnancy, pre ecclampsia and 
8-10gestational diabetes . African American race, obesity, 
maternal cocaine and alcohol abuse, smoking and long 
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CURRENT MANAGEMENT OF PERIPARTUM 
CARDIOMYOPATHY: A REVIEW
BACKGROUND
Demarkis et al in 1971 described 27 patients who presented during pueperium with cardiomegaly, abnormal 
electrocardiographic findings, congestive heart failure and named the syndrome “peripartum cardiomyopathy”. The 
aim of this review is to document the current concepts in the management  of peripartum cardiomyopathy.
MATERIALS AND METHODS
A search of the literature was done using PubMed, Goggle scholar and books from authors' collections.
RESULTS
The cause of the disease might be environmental and genetic factors. Diagnostic echocardiographic criteria include 
left ventricular ejection fraction of less than 45% or a combination of M- mode fractional shortening of less than 30% 
2and end diastolic dimension of greater than 2.7cm/m . Electrocardiogram, magnetic resonance imaging, 
endomyocardial biopsy and cardiac catheterization aid in the diagnosis and management of peripartum 
cardiomyopathy. Treatment includes both conventional pharcomological heart failure and peripartum 
cardiomyopathy targeted therapies. Therapeutic decisions are influenced by drug safety profiles during pregnancy and 
lactation. Mechanical support and transplantation might be necessary in severe cases.
CONCLUSION
Peripartum cardiomyopathy is an uncommon but life threatening cardiac failure of unknown aetiology encountered in 
late pregnancy or postpartum period. Management aims at improving heart failure symptoms through conventional 
therapies and then at administering targeted therapies. The risk of recurrence in future pregnancies should always be 
considered.
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lower left ventricular ejection fractions at 
presentation.
25In the studies of left ventricular dysfunction , 
circulating levels of tumor necrosis factor 
alpha and interleukin 6 increased in patients as 
their functional heart failure classification 
deteroriated.
E) AN ABNORMAL HAEMODYNAMIC 
RESPONSE: During pregnancy, blood volume 
and cardiac output increase. In addition, 
afterload decreases because of relaxation of 
vascular smooth muscle. The increases in 
volume and cardiac output during pregnancy 
cause transient and reversible hypertrophy of 
the left ventricle to meet the needs of the 
mother and foetus. Cardiac output reaches its 
26maximum around 20 weeks of pregnancy . 
The transient left ventricular systolic 
dysfunction during the third trimester and 
early post partum period returns to baseline 
27once the cardiac output decreases .
CLINICAL FEATURES AND DIAGNOSIS
Postpartum cardiomyopathy involves the left 
ventricular dysfunction in women with no history of 
heart disease. It can be diagnosed only if other causes of 
2cardiomyopathy are absent . Diagnostic criteria for PC 
28include :
1) Cardiac failure developing in the last month of 
pregnancy or within 5 months of delivery.
2) No identifiable cause of cardiac failure.
3) No recognizable heart disease before the last 
month of pregnancy.
4) An ejection fraction of less than 45% or the 
combination of an M-mode fractional 
shortening of less than 30% and an end-
2diastolic dimension greater than 2.7cm/m . 
Symptoms of PC are similar in patients with systolic 
dysfunction who are not pregnant. New or rapid onset 
of symptoms like cough, orthopnoea, paroxysmal 
nocturnal dyspnea, fatigue, palpitations, weight gain, 
haemoptysis, chest pain and unexplained abdominal 
1 1pain  would  require  prompt  eva luat ion .
Physical evaluation frequently reveals enlarged heart, 
tachycardia and decreased pulse oximetry. There may 
be abnormal blood pressure, elevated jugular venous 
pressure, third heart sound, mitral and/or tricuspid 
regurgitation and pulmonary rales. Worsening of 
peripheral oedema, ascites, hepatomegaly and 
11arrhythmias are frequently seen . There may also be 
s m a l l  t o  m o d e r a t e  p e r i p h e r a l  o e d e m a .
Generally, clinical presentation and haemodynamic 
changes are indistinguishable from those found in 
29other forms of dilated cardiomyopathy . High output 
cardiac failure has also been recorded in a few 
30patients .
AETIOPATHOGENESIS
Although the aetiology of PC is still unknown, some 
plausible causes have been identified but none of them 
12,13is definite . They include
A) NUTRITIONAL FACTORS: Higher incidence 
in some African countries has been attributed 
to the consumption of “Kanwa”, a tradition for 
1140 postpartum days . Kanwa is a dry salt and 
causes hypervolaemia and hypertension. 
Ninety percent of PC occurs within 2 months of 
11delivery .
B) MYOCARDITIS: Myocarditis has beenfound 
on endometrial biopsy of the right ventricle in 
14patients with PC with a dense lymphocytic 
infiltrate and variable amounts of myocyte 
oedema,necrosis and fibrosis. The prevalence 
of myocarditis in patients with PC ranged from 
15,168.8 to 78% in different studies . On the other 
hand, the presence or absence of myocarditis 
17alone does not predict its outcome .
C) CHEMERISM: In this phenomenon, cells from 
the fetus take up residence in the mother (or 
vice versa), sometimes provoking an immune 
18,19response .
The serum of patients with PC has been found 
to contain auto antibodies in high titres, which 
are not present in serum from patients with 
20idiopathic cardiomyopathy . Most of these 
antibodies are against normal human cardiac 
tissue proteins of 37, 33, and 25KD.
Multiparty is a risk factor for the development 
of this disorder suggesting that previous 
exposure to fetal or paternal antigen may elicit 
an abnormal myocardial infiltrative response. 
The timing of presentation in the immediate 
postpartum period supports an autoimmune 
21pathogenesis .
D) APOPTOSIS AND INFLAMMATION: 
Apoptosis (programmed cell death) of cardiac 
myocytes occur in heart failure and may 
contribute to progressive myocardial 
22dysfunction . Experiments in mice suggest 
that apoptosis of cardiac myocytes has a role in 
23Pc .
Fas and Fas ligand are cell surface proteins that 
24play a key role in apoptosis. Sliwaet al  in a 
single center prospective, longitudinal study 
from South Africa, followed 100 patients with 
peripartum cardiomyopathy for 6 months. 
During this time, 15 patients died and those 
who died had significantly higher levels of 
Fas/Apo-1 (p ?  0.05). in the same study, 
plasma levels of c- reactive protein and tumor 
n e c r o s i s  f a c t o r  a l p h a  ( m a r k e r s  o f  
inflammation) were elevated and correlated 
with higher left ventricular dimensions and 
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converting enzyme (ACE) inhibitors and 
Angiotensin receptor blockers (ARBs) are 
useful. The usual target dose is one half the 
maximum antihypertensive dose. Diuretics 
a r e  g i v e n  f o r  s y m p t o m a t i c  r e l i e f .  
Spironolactone or digoxin is used in patients 
who have New York Heart Association class lll 
or lV symptoms. The dose of spironolactone is 
25mg daily after dosing of other drugs is 
maximized. The goal with digoxin is the lowest 
daily dose to obtain a detectable serum digoxin 
level which should be kept at less than 
111.0ng/ml . Beta blockers are recommended 
for peripartum cardiomyopathy as they 
improve symptoms, ejection fraction and 
35survival . Non selective beta blockers like 
carvedilol with a goal dosage of 25mg twice a 
day and selective beta blockers likemetoprolol 
with a goal dosage of 100mg once a day have 
11shown benefit . 
ANTICOAGULANT TREATMENT
There is an increase risk of thromboembolic 
complications during pregnancy due to higher 
concentrations of coagulation factors ll,VII,VIII,X and 
fibrinogen and this may persist up to 6 weeks post 
1partum . Cases of arterial, venous and cardiac 
thrombosis have been reported in women with 
peripartum cardiomyopathy and the risk may be 
related to the degree of chamber enlargement and 
systolic dysfunction and the presence of atrial 
38fibrillation . Therefore, the use of heparin is advocated 
in the antepartum period and that of heparin and 
warfarin in the postpartum period as warfarin is 
contraindicated in pregnancy because of its teratogenic 
effect while use of both heparin and warfarin is safe in 
39lactation . Patients with evidence of systemic 
embolism with systemic left ventricular dysfunction or 
documented cardiac thrombosis should receive 
3 8anticoagulation . Anticoagulation should be 
continued until the return of normal left ventricular 
function is documented.
ANTIARRHYTHMIC DRUGS
In patients presenting with ventricular tachycardia 
with haemodynamic compromise, an implantable 
40cardioverterdefribrillator may be used . For patients 
with symptomatic ventricular tachyarrhythmia who 
are haemodynamically well tolerated, management 
can be tempered by the potential transient nature of the 
myopathyand amiodarone therapy at 200 to 400mg 
11orally 6hourly is an alternative . If left ventricular 
function recovers, the risk of serious arrhythmic event 
is markedly diminished and amiodarone therapy can 
11be discontinued .For patients with asymptomatic non 
sustained ventricular tachyarrhythmia, the focus is on 
correction of metabolic abnormalities and addition of a 
beta receptor antagonist (if not already being utilized).
Pre ecclampsia should be excluded. It occurs after 20 
weeks of gestation and ic characterized by high blood 
pressure, proteinuria, pitting pedal oedema, sudden 
weight gain, headaches and changes in vision. A latent 
form of PC without clinical signs and symptoms has 
31been reported .
The aims during diagnosis are to exclude other causes 
of cardiomyopathy and to confirm left ventricular 
systolic dysfunction by echocardiography. Whether 
endomyocardial biopsy should be done in this setting 
is still controversial and recent guidelines do not 
32recommend it .
Magnetic Resonance Imaging (MRI) may be used as a 
complementary tool to diagnose PC and also identify 
the mechanisms involved. It can measure global and 
segmental myocardial contraction and it can 
33 34characterize the myocardium . Leurentet al  advocate 
using cardiac MRI to guide biopsy of the abnormal 
area. This may be more useful than blind biopsy.
TREATMENT
1) DURING PREGNANCY: Early diagnosis and 
treatment are keys to a successful outcome. 
The welfare of the fetus is considered along 
with that of the mother. Multidisciplinary 
approach involving the physician and 
obstetrician is essential. Oxygen therapy 
should be promptly administered in acute 
heart failure to relieve symptoms, with a target 
arterial saturation of ≥ 95%.Digoxin, beta 
blockers, loop diuretics and drugs that reduce 
afterload such as hydralazine and nitrates are 
safe and are the mainstay of medical therapy of 
35heart failure during pregnancy . Digoxin is 
effective due to its inotropic and rate reducing 
effects while diuretics are useful in reduction 
11of preload and salt restriction . Even though, 
they are relatively safe in pregnancy, there 
should be caution regarding volume depletion 
leading to dehydration and consequent 
36uterine hypoperfusion and fetal distress .In 
patients with persistent congestion despite 
diuretic and or vasodilator therapy, 
dobutamine or levosimendan are strongly 
recommended. Beta blockers have strong 
evidenceof efficacy in patients with heart 
failure but they have not been tested in PC. 
However, they have long been used in 
pregnant women with hypertension without 
any known adverse effect on the fetus, and 
patients taking these agents prior to diagnosis 
37can continue to use them safely .
2) DURING POST PARTUM PERIOD: Treatment 
is identical to that ofnon-pregnant women 
with dilated cardiomyopathy. Angiotensin 
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prognosis remains guarded and mortality rate 
47as high as 10-50% has been reported . Factors 
predicting normalization of left ventricular 
function were an initial left ventricular end 
48 49systolic dimension of 5.5cm or less  or 30%
2) Left ventricular size: It's an important 
predictor as women presenting without 
significant left ventricular dilatation appeared 
to have greater chance of spontaneous 
11recovery during follow up . In contrast, 
women with marked left ventricular dilatation 
at presentation appeared to have a greater 
likelihood of developing into chronic 
11cardiomyopathy .
503) TROPONIN T: Hu et al  reported that the 
serum cardiac troponin T concentration 
measured 2 weeks after the onset of 
peripartum cardiomyopathy correlated 
inversely with the left ventricular ejection 
fraction at 6 months. However, the sensitivity 
was low: a troponin T concentration of 
? 0.04ng/ml predicted left ventricular 
dysfunction with a sensitivity of only 50% and 
50specificity of 91% .
4) QRS Duration of ≥ 120ms has been identified 
51as a predictor of death .
RECOMMENDATIONS
1) If left ventricular ejection fraction is < 25% at 
diagnosis or failure to recover following 
treatment, the advice should be against further 
13pregnancies .
2) If left ventricular function is normal, the 
p a t i e n t s  o u g h t  t o  h a v e  s t r e s s  
echocardiography: women with an abnormal 
left ventricular inotropic response to 
dobutamine have a moderate risk of relapse 
52and pregnancy is not recommended .
3) Women with complete recovery on both 
echocardiography and dobutamine stress test 
can be informed about the low rate of 
complications. In this group, despite a 35% rate 
of risk of recurrence, pregnancy can be 
52completed in almost all cases .
4) In the postpartum period, it is imperative to 
give contraceptive counseling and educate the 
patient about the existent alternatives and 
women who had PC should avoid pregnancy 
until left ventricular function has recovered. 
The combined oral contraceptives containing 
oestrogen and progestin are contraindicated as 
oestrogenincreases the thromboembolic risk. 
Progesterone contraception alone is  
53permitted . Vasectomy, tubal ligation and 




Patients with severe heart failure despite maximal drug 
therapy need cardiac transplantation to survive and 
11improve their quality of life . However, since fewer 
than 3000 hearts are available for transplantation 
worldwide per year, ventricular assisted devices are 
41indicated as a bridge to transplantation .
CURRENT CONCEPTS
1) PENTOXIFYLLINE: This is a xanthine derived 
agent known to inhibit the production of 
tumor necrosis factor alpha (which is elevated 
in these patients). It improves outcomes, left 
ventricular function and symptoms when 
added to conventional therapy in small 
42prospective study .
2) BROMOCRIPTINE: Recently, some studies 
have suggested the role of prolactin 
breakdown products in the aetiology of 
43peripartum cardiomyopathy . Prolactin 
secretion can be reduced with bromocriptine 
44which had beneficial effects in small study . In 
one study with the use of cabergoline which is 
a strong and long lasting antagonist of 
prolactin, significant improvement in left 
45ventricular functions was reported .
3) IMMUNOMODULATING THERAPY:  
Immunosuppressive and immunomodulatory 
therapy have been used due to the 
inf lammatory nature  of  peripartum 
cardiomyopathy and the occasional  
appearance of myocarditis on endomyocardial 
biopsy. Intravenous immunoglobulin 
improved the ejection fraction in several 
studies and also markedly reduced the levels 
46of inflammatory cytokines . Plasmapharesis 
has also been tried and may be used as an 
alternative to immunoglobulin therapy in 
1 1p e r i p a r t u m  c a r d i o m y o p a t h y .
Other proposed therapies which might be 
useful are calcium channel antagonists, statins, 
11monoclonal antibodies and interferon beta .
PROGNOSIS
1) Left ventricular function: Women with 
peripartum cardiomyopathy have a high rate 
of spontaneous recovery of left ventricular 
function. On echocardiography in postpartum 
period, nearly half of the women will 
normalize ejection fraction during follow up 
within 6 months .The prognosis is directly 
correlated to recovery of left ventricular 
function. For those women whose left 
ventricular function normalizes during follow 
up, the prognosis is excellent. In women whose 
left ventricular function does not recover, 
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